Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lehtimäki K[au]:

Surgery or conservative treatment for rotator cuff tear: a meta-analysis. Ryösä A et al. Disabil Rehabil. (2017)

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease. Zeitler B et al. Nat Med. (2019)

Deep brain stimulation targeting in refractory epilepsy. Cukiert A et al. Epilepsia. (2017)

Search results

Items: 1 to 50 of 73

1.

Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice.

Datson NA, Bijl S, Janson A, Testerink J, van den Eijnde R, Weij R, Puoliväli J, Lehtimäki K, Bragge T, Ahtoniemi T, van Deutekom JC.

Nucleic Acid Ther. 2020 Feb;30(1):50-65. doi: 10.1089/nat.2019.0824. Epub 2019 Dec 10.

PMID:
31821107
2.

Improved synthesis of [18F] fallypride and characterization of a Huntington's disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors.

Huhtala T, Poutiainen P, Rytkönen J, Lehtimäki K, Parkkari T, Kasanen I, Airaksinen AJ, Koivula T, Sweeney P, Kontkanen O, Wityak J, Dominiquez C, Park LC.

EJNMMI Radiopharm Chem. 2019 Aug 5;4(1):20. doi: 10.1186/s41181-019-0071-6.

3.

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.

Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, Pearl JR, Miller JC, Zhang L, Paschon DE, Hinkley SJ, Ankoudinova I, Lam S, Guschin D, Kopan L, Cherone JM, Nguyen HB, Qiao G, Ataei Y, Mendel MC, Amora R, Surosky R, Laganiere J, Vu BJ, Narayanan A, Sedaghat Y, Tillack K, Thiede C, Gärtner A, Kwak S, Bard J, Mrzljak L, Park L, Heikkinen T, Lehtimäki KK, Svedberg MM, Häggkvist J, Tari L, Tóth M, Varrone A, Halldin C, Kudwa AE, Ramboz S, Day M, Kondapalli J, Surmeier DJ, Urnov FD, Gregory PD, Rebar EJ, Muñoz-Sanjuán I, Zhang HS.

Nat Med. 2019 Jul;25(7):1131-1142. doi: 10.1038/s41591-019-0478-3. Epub 2019 Jul 1.

PMID:
31263285
4.

Autostimulation in Vagus Nerve Stimulator Treatment: Modulating Neuromodulation.

Kulju T, Haapasalo J, Rainesalo S, Lehtimäki K, Peltola J.

Neuromodulation. 2019 Jul;22(5):630-637. doi: 10.1111/ner.12897. Epub 2018 Dec 14.

PMID:
30549376
5.

Tardive Dyskinesia Should Not Be Overlooked.

Kakko K, Bjelogrlic-Laakso N, Pihlakoski L, Lehtimäki K, Järventausta K.

J Child Adolesc Psychopharmacol. 2019 Feb;29(1):72-74. doi: 10.1089/cap.2018.0084. Epub 2018 Nov 2. No abstract available.

PMID:
30388034
6.

Reversible psychiatric adverse effects related to deep brain stimulation of the anterior thalamus in patients with refractory epilepsy.

Järvenpää S, Peltola J, Rainesalo S, Leinonen E, Lehtimäki K, Järventausta K.

Epilepsy Behav. 2018 Nov;88:373-379. doi: 10.1016/j.yebeh.2018.09.006. Epub 2018 Oct 2.

7.

Effect of electroconvulsive therapy on brain-derived neurotrophic factor levels in patients with major depressive disorder.

Sorri A, Järventausta K, Kampman O, Lehtimäki K, Björkqvist M, Tuohimaa K, Hämäläinen M, Moilanen E, Leinonen E.

Brain Behav. 2018 Nov;8(11):e01101. doi: 10.1002/brb3.1101. Epub 2018 Oct 1.

8.

Executive Functions May Predict Outcome in Deep Brain Stimulation of Anterior Nucleus of Thalamus for Treatment of Refractory Epilepsy.

Järvenpää S, Rosti-Otajärvi E, Rainesalo S, Laukkanen L, Lehtimäki K, Peltola J.

Front Neurol. 2018 May 8;9:324. doi: 10.3389/fneur.2018.00324. eCollection 2018.

9.

Risk and risk factors for revision after primary reverse shoulder arthroplasty for cuff tear arthropathy and osteoarthritis: a Nordic Arthroplasty Register Association study.

Lehtimäki K, Rasmussen JV, Mokka J, Salomonsson B, Hole R, Jensen SL, Äärimaa V.

J Shoulder Elbow Surg. 2018 Sep;27(9):1596-1601. doi: 10.1016/j.jse.2018.02.060. Epub 2018 May 18.

PMID:
29779980
10.

Similarities between the responses to ANT-DBS and prior VNS in refractory epilepsy.

Kulju T, Haapasalo J, Lehtimäki K, Rainesalo S, Peltola J.

Brain Behav. 2018 Jun;8(6):e00983. doi: 10.1002/brb3.983. Epub 2018 May 8.

11.

Low tumor necrosis factor-α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder.

Sorri A, Järventausta K, Kampman O, Lehtimäki K, Björkqvist M, Tuohimaa K, Hämäläinen M, Moilanen E, Leinonen E.

Brain Behav. 2018 Feb 22;8(4):e00933. doi: 10.1002/brb3.933. eCollection 2018 Apr.

12.

The Surgical Approach to the Anterior Nucleus of Thalamus in Patients With Refractory Epilepsy: Experience from the International Multicenter Registry (MORE).

Lehtimäki K, Coenen VA, Gonçalves Ferreira A, Boon P, Elger C, Taylor RS, Ryvlin P, Gil-Nagel A, Gielen F, Brionne TC, Abouihia A, Beth G; MORE investigators.

Neurosurgery. 2019 Jan 1;84(1):141-150. doi: 10.1093/neuros/nyy023.

PMID:
29554309
13.

Stimulation Induced Electrographic Seizures in Deep Brain Stimulation of the Anterior Nucleus of the Thalamus Do Not Preclude a Subsequent Favorable Treatment Response.

Nora T, Heinonen H, Tenhunen M, Rainesalo S, Järvenpää S, Lehtimäki K, Peltola J.

Front Neurol. 2018 Feb 19;9:66. doi: 10.3389/fneur.2018.00066. eCollection 2018.

14.

Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Collier AF, Gumerson J, Lehtimäki K, Puoliväli J, Jones JW, Kane MA, Manne S, O'Neill A, Windish HP, Ahtoniemi T, Williams BA, Albrecht DE, Bloch RJ.

J Pharmacol Exp Ther. 2018 Mar;364(3):409-419. doi: 10.1124/jpet.117.244244. Epub 2017 Dec 28.

15.

The production of IL-6 in acute epileptic seizure: A video-EEG study.

Alapirtti T, Lehtimäki K, Nieminen R, Mäkinen R, Raitanen J, Moilanen E, Mäkinen J, Peltola J.

J Neuroimmunol. 2018 Mar 15;316:50-55. doi: 10.1016/j.jneuroim.2017.12.008. Epub 2017 Dec 15.

PMID:
29273305
16.

Causal Evidence from Humans for the Role of Mediodorsal Nucleus of the Thalamus in Working Memory.

Peräkylä J, Sun L, Lehtimäki K, Peltola J, Öhman J, Möttönen T, Ogawa KH, Hartikainen KM.

J Cogn Neurosci. 2017 Dec;29(12):2090-2102. doi: 10.1162/jocn_a_01176. Epub 2017 Aug 4.

PMID:
28777058
17.

Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy.

Potter RA, Griffin DA, Sondergaard PC, Johnson RW, Pozsgai ER, Heller KN, Peterson EL, Lehtimäki KK, Windish HP, Mittal PJ, Albrecht DE, Mendell JR, Rodino-Klapac LR.

Hum Gene Ther. 2018 Jul;29(7):749-762. doi: 10.1089/hum.2017.062. Epub 2017 Jul 13.

18.

Cranioplasty with Adipose-Derived Stem Cells, Beta-Tricalcium Phosphate Granules and Supporting Mesh: Six-Year Clinical Follow-Up Results.

Thesleff T, Lehtimäki K, Niskakangas T, Huovinen S, Mannerström B, Miettinen S, Seppänen-Kaijansinkko R, Öhman J.

Stem Cells Transl Med. 2017 Jul;6(7):1576-1582. doi: 10.1002/sctm.16-0410. Epub 2017 May 15.

19.

Vagus nerve stimulation improves working memory performance.

Sun L, Peräkylä J, Holm K, Haapasalo J, Lehtimäki K, Ogawa KH, Peltola J, Hartikainen KM.

J Clin Exp Neuropsychol. 2017 Dec;39(10):954-964. doi: 10.1080/13803395.2017.1285869. Epub 2017 Feb 19.

PMID:
28492363
20.

Deep brain stimulation targeting in refractory epilepsy.

Cukiert A, Lehtimäki K.

Epilepsia. 2017 Apr;58 Suppl 1:80-84. doi: 10.1111/epi.13686. Review.

21.

Hip region muscular dystrophy and emergence of motor deficits in dysferlin-deficient Bla/J mice.

Nagy N, Nonneman RJ, Llanga T, Dial CF, Riddick NV, Hampton T, Moy SS, Lehtimäki KK, Ahtoniemi T, Puoliväli J, Windish H, Albrecht D, Richard I, Hirsch ML.

Physiol Rep. 2017 Mar;5(6). pii: e13173. doi: 10.14814/phy2.13173.

22.

The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain.

Datson NA, González-Barriga A, Kourkouta E, Weij R, van de Giessen J, Mulders S, Kontkanen O, Heikkinen T, Lehtimäki K, van Deutekom JC.

PLoS One. 2017 Feb 9;12(2):e0171127. doi: 10.1371/journal.pone.0171127. eCollection 2017.

23.

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, Gleyzes M, Wadel K, Buisson B, Padovan-Neto FE, Chakroborty S, Ward KM, Harms JF, Beltran J, Kwan M, Ghavami A, Häggkvist J, Tóth M, Halldin C, Varrone A, Schaab C, Dybowski JN, Elschenbroich S, Lehtimäki K, Heikkinen T, Park L, Rosinski J, Mrzljak L, Lavery D, West AR, Schmidt CJ, Zaleska MM, Munoz-Sanjuan I.

Neuron. 2016 Dec 21;92(6):1220-1237. doi: 10.1016/j.neuron.2016.10.064. Epub 2016 Dec 1.

24.

Successful management of super-refractory status epilepticus with thalamic deep brain stimulation.

Lehtimäki K, Långsjö JW, Ollikainen J, Heinonen H, Möttönen T, Tähtinen T, Haapasalo J, Tenhunen J, Katisko J, Öhman J, Peltola J.

Ann Neurol. 2017 Jan;81(1):142-146. doi: 10.1002/ana.24821. Epub 2016 Dec 28.

PMID:
27862207
25.

Changes in interleukin-6 levels during electroconvulsive therapy may reflect the therapeutic response in major depression.

Järventausta K, Sorri A, Kampman O, Björkqvist M, Tuohimaa K, Hämäläinen M, Moilanen E, Leinonen E, Peltola J, Lehtimäki K.

Acta Psychiatr Scand. 2017 Jan;135(1):87-92. doi: 10.1111/acps.12665. Epub 2016 Nov 14.

PMID:
27858966
26.

Critical neural targets for (the level of) human consciousness: Arousal arrest and unconsciousness after sumatriptan administration.

Långsjö JW, Lehtimäki K, Ruohonen J, Sajanti A, Sandell S, Heikkilä HT, Brander A, Saarinen K, Herrala L.

Brain Inj. 2016;30(13-14):1731-1736. Epub 2016 Sep 28.

PMID:
27680211
27.

Imaging of Anterior Nucleus of Thalamus Using 1.5T MRI for Deep Brain Stimulation Targeting in Refractory Epilepsy.

Jiltsova E, Möttönen T, Fahlström M, Haapasalo J, Tähtinen T, Peltola J, Öhman J, Larsson EM, Kiekara T, Lehtimäki K.

Neuromodulation. 2016 Dec;19(8):812-817. doi: 10.1111/ner.12468. Epub 2016 Jul 11.

PMID:
27398710
28.

Surgery or conservative treatment for rotator cuff tear: a meta-analysis.

Ryösä A, Laimi K, Äärimaa V, Lehtimäki K, Kukkonen J, Saltychev M.

Disabil Rehabil. 2017 Jul;39(14):1357-1363. doi: 10.1080/09638288.2016.1198431. Epub 2016 Jul 6. Review.

PMID:
27385156
29.

CSF and plasma adipokines after tonic-clonic seizures.

Palmio J, Vuolteenaho K, Lehtimäki K, Nieminen R, Peltola J, Moilanen E.

Seizure. 2016 Jul;39:10-12. doi: 10.1016/j.seizure.2016.04.010. Epub 2016 May 4.

30.

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.

Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, Tombaugh G, Gelman S, Bradaia A, Steidl E, Gleyzes M, Heikkinen T, Lehtimäki K, Puoliväli J, Kontkanen O, Javier RM, Neagoe I, Deisemann H, Winkler D, Ebneth A, Khetarpal V, Toledo-Sherman L, Dominguez C, Park LC, Munoz-Sanjuan I.

Exp Neurol. 2016 Aug;282:99-118. doi: 10.1016/j.expneurol.2016.05.005. Epub 2016 May 6.

PMID:
27163548
31.

The Correlation between Intraoperative Microelectrode Recording and 3-Tesla MRI in Patients Undergoing ANT-DBS for Refractory Epilepsy.

Möttönen T, Katisko J, Haapasalo J, Tähtinen T, Saastamoinen A, Peltola J, Öhman J, Lehtimäki K.

Stereotact Funct Neurosurg. 2016;94(2):86-92. doi: 10.1159/000444761. Epub 2016 Apr 20.

PMID:
27093608
32.

Outcome based definition of the anterior thalamic deep brain stimulation target in refractory epilepsy.

Lehtimäki K, Möttönen T, Järventausta K, Katisko J, Tähtinen T, Haapasalo J, Niskakangas T, Kiekara T, Öhman J, Peltola J.

Brain Stimul. 2016 Mar-Apr;9(2):268-75. doi: 10.1016/j.brs.2015.09.014. Epub 2015 Oct 9.

33.

Human anterior thalamic nuclei are involved in emotion-attention interaction.

Sun L, Peräkylä J, Polvivaara M, Öhman J, Peltola J, Lehtimäki K, Huhtala H, Hartikainen KM.

Neuropsychologia. 2015 Nov;78:88-94. doi: 10.1016/j.neuropsychologia.2015.10.001. Epub 2015 Oct 18.

34.

Defining the anterior nucleus of the thalamus (ANT) as a deep brain stimulation target in refractory epilepsy: Delineation using 3 T MRI and intraoperative microelectrode recording.

Möttönen T, Katisko J, Haapasalo J, Tähtinen T, Kiekara T, Kähärä V, Peltola J, Öhman J, Lehtimäki K.

Neuroimage Clin. 2015 Mar 5;7:823-9. doi: 10.1016/j.nicl.2015.03.001. eCollection 2015.

35.

mNos2 deletion and human NOS2 replacement in Alzheimer disease models.

Colton CA, Wilson JG, Everhart A, Wilcock DM, Puoliväli J, Heikkinen T, Oksman J, Jääskeläinen O, Lehtimäki K, Laitinen T, Vartiainen N, Vitek MP.

J Neuropathol Exp Neurol. 2014 Aug;73(8):752-69. doi: 10.1097/NEN.0000000000000094.

36.

Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.

Menalled LB, Kudwa AE, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, Mazzella M, He D, Osborne GF, Al-Nackkash R, Bates GP, Tuunanen P, Lehtimaki K, Brunner D, Ghavami A, Ramboz S, Park L, Macdonald D, Munoz-Sanjuan I, Howland D.

PLoS One. 2014 Jun 23;9(6):e99520. doi: 10.1371/journal.pone.0099520. eCollection 2014.

37.

Immediate effects of deep brain stimulation of anterior thalamic nuclei on executive functions and emotion-attention interaction in humans.

Hartikainen KM, Sun L, Polvivaara M, Brause M, Lehtimäki K, Haapasalo J, Möttönen T, Väyrynen K, Ogawa KH, Öhman J, Peltola J.

J Clin Exp Neuropsychol. 2014;36(5):540-50. doi: 10.1080/13803395.2014.913554. Epub 2014 May 19.

38.

Progressive volume loss and white matter degeneration in cstb-deficient mice: a diffusion tensor and longitudinal volumetry MRI study.

Manninen O, Laitinen T, Lehtimäki KK, Tegelberg S, Lehesjoki AE, Gröhn O, Kopra O.

PLoS One. 2014 Mar 6;9(6):e90709. doi: 10.1371/journal.pone.0090709. eCollection 2014.

39.

The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease.

Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, Munoz-Sanjuan I.

PLoS Curr. 2014 Feb 13;6. pii: ecurrents.hd.3304e87e460b4bb0dc519a29f4deccca. doi: 10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca.

40.

Immunological perspectives of temporal lobe seizures.

Liimatainen S, Lehtimäki K, Palmio J, Alapirtti T, Peltola J.

J Neuroimmunol. 2013 Oct 15;263(1-2):1-7. doi: 10.1016/j.jneuroim.2013.08.001. Epub 2013 Aug 13. Review. Erratum in: J Neuroimmunol. 2014 Feb 15;267(1-2):113. Kai, Lehtimäki [corrected to Lehtimäki, Kai];Johanna, Palmio [corrected to Palmio, Johanna]; Tiina, Alapirtti [corrected to Alapirtti, Tiina]; Jukka, Peltola [corrected to Peltola, Jukka].

PMID:
23998423
41.

White matter degeneration with Unverricht-Lundborg progressive myoclonus epilepsy: a translational diffusion-tensor imaging study in patients and cystatin B-deficient mice.

Manninen O, Koskenkorva P, Lehtimäki KK, Hyppönen J, Könönen M, Laitinen T, Kalimo H, Kopra O, Kälviäinen R, Gröhn O, Lehesjoki AE, Vanninen R.

Radiology. 2013 Oct;269(1):232-9. doi: 10.1148/radiol.13122458. Epub 2013 Jun 20.

PMID:
23788720
42.

Clinical significance of treatment delay in status epilepticus.

Hillman J, Lehtimäki K, Peltola J, Liimatainen S.

Int J Emerg Med. 2013 Feb 27;6(1):6. doi: 10.1186/1865-1380-6-6.

43.

Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.

Heikkinen T, Lehtimäki K, Vartiainen N, Puoliväli J, Hendricks SJ, Glaser JR, Bradaia A, Wadel K, Touller C, Kontkanen O, Yrjänheikki JM, Buisson B, Howland D, Beaumont V, Munoz-Sanjuan I, Park LC.

PLoS One. 2012;7(12):e50717. doi: 10.1371/journal.pone.0050717. Epub 2012 Dec 20.

44.
45.

Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.

Gafni J, Papanikolaou T, Degiacomo F, Holcomb J, Chen S, Menalled L, Kudwa A, Fitzpatrick J, Miller S, Ramboz S, Tuunanen PI, Lehtimäki KK, Yang XW, Park L, Kwak S, Howland D, Park H, Ellerby LM.

J Neurosci. 2012 May 30;32(22):7454-65. doi: 10.1523/JNEUROSCI.6379-11.2012.

46.

Multimodal MRI assessment of damage and plasticity caused by status epilepticus in the rat brain.

Gröhn O, Sierra A, Immonen R, Laitinen T, Lehtimäki K, Airaksinen A, Hayward N, Nairismagi J, Lehto L, Pitkänen A.

Epilepsia. 2011 Oct;52 Suppl 8:57-60. doi: 10.1111/j.1528-1167.2011.03239.x. Review.

47.

The radical scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) decreases mortality, enhances cognitive functions in water maze and reduces amyloid plaque burden in hAβPP transgenic mice.

Puoliväli J, Nurmi A, Miettinen TK, Soleti A, Riccardino F, Kalesnykas G, Heikkinen T, Vartiainen N, Pussinen R, Tähtivaara L, Lehtimäki K, Yrjänheikki J, Canistro D, Sapone A, Spisni E, Paolini M.

J Alzheimers Dis. 2011;27(3):499-510. doi: 10.3233/JAD-2011-110881.

PMID:
21821875
48.

The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy.

Lehtimäki KA, Liimatainen S, Peltola J, Arvio M.

Epilepsy Res. 2011 Jun;95(1-2):184-7. doi: 10.1016/j.eplepsyres.2011.03.004. Epub 2011 Apr 29.

PMID:
21530175
49.

Cardiolipin and β₂-Glycoprotein I antibodies associate with cognitive impairment and seizure frequency in developmental disorders.

Lehtimäki KA, Peltola J, Liimatainen S, Haapala AM, Arvio M.

Seizure. 2011 Jul;20(6):438-41. doi: 10.1016/j.seizure.2011.01.018. Epub 2011 Mar 5.

50.

Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy.

Liimatainen S, Lehtimäki K, Raitala A, Peltola M, Oja SS, Peltola J, Hurme MA.

Epilepsy Res. 2011 May;94(3):206-12. doi: 10.1016/j.eplepsyres.2011.02.003. Epub 2011 Mar 4.

PMID:
21377330

Supplemental Content

Loading ...
Support Center